Ethan J. Subel

Ethan J. Subel

Auto-generated profile, based on publicly available information

Ethan J. Subel

Department of Urology, Houston Methodist Research Institute, Houston, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2025 in Science Advances
Verified
Journal Article
Open access
HGHongbo Gao
Hongbo Gao
SWStephen Q. R. Wong
Stephen Q. R. Wong
ESEthan Subel
Ethan Subel
YHYung Huang
Yung Huang
YLYu-Cheng Lee
Yu-Cheng Lee
KCKeith Syson Chan
Keith Syson Chan
The impact of chemotherapy-induced tumor cell pyroptosis on fibroblasts, a key stromal cell type within the tumor microenvironment (TME), remains unexplored. Here, we report morphologically and molecularly distinct subtypes of cancer-associated fibroblasts (CAFs) in bladder cancer, including αSMA + IL-6 − myofibroblastic CAFs (myCAFs), αSMA − IL-6 + inflammatory CAFs (iCAFs), and hybrid i/myCAFs. Caspase-1–dependent tumor pyroptosis releases several inflammatory chemokines, converting αSMA + CAF into iCAFs in a CCR6-dependent manner. This is clinically relevant, as a fibroblast gene signature driven by iCAF markers and collagen type III is enriched in patients with chemoresistant bladder cancer after neoadjuvant chemotherapy. Contrary to the current notion, iCAFs, rather than myCAFs, produce collagen III in response to chemotherapy, supporting the expansion of cancer stem cells (CSCs). Thus, tumor cell pyroptosis initiates an iCAF-CSC feedforward loop that drives chemoresistance, indicating that inflammatory cell death is not universally beneficial to anticancer therapy, depending on the target cell type.

20 April 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
SWStephen Qr Wong
Stephen Qr Wong
KHKazukuni Hayashi
Kazukuni Hayashi
ESEthan J. Subel
Ethan J. Subel
YHYung Huang
Yung Huang
HGHongbo Gao
Hongbo Gao
KCKeith S. Chan
Keith S. Chan
While chemotherapy-induced tumor cell death is known to modulate the local immune landscape, its systemic impact on distant bone marrow—a site essential for immune cell maturation—remains underexplored. Here, we show that gemcitabine chemotherapy induces inflammatory caspase-1-dependent pyroptosis in epithelial cancer cells (epiCaspase-1). Despite its inflammatory nature, epiCaspase-1-mediated cell death is non-immunogenic. Clinically, elevated expression of an epiCaspase-1 gene signature correlates with worse patient outcomes. Mechanistically, epiCaspase-1 triggers the noncanonical release of IL-1α through NINJ1 lytic pores, remotely skewing bone marrow hematopoiesis towards granulocyte-monocyte progenitors and mature neutrophil output. This systemic reprogramming elevates the neutrophil-to-lymphocyte ratio (NLR) in both peripheral blood and the local tumor microenvironment. Pharmacological inhibition of caspase-1 and IL-1α disrupts this cascade, normalizes hematopoiesis, and recalibrates NLR by promoting intratumoral CD8+ T cell infiltration and activation, ultimately enhancing chemotherapeutic efficacy. These findings challenge the assumption that inflammatory pyroptosis is inherently immunogenic; instead, it can reshape systemic immune landscape towards a neutrophil-dominant inflammation in the chemotherapy context.